This advanced, high-level consultation package represents the highest level of review for complex cases. It includes a comprehensive and in-depth immunohistochemical analysis of eleven or more immunohistochemical (IHC) results. The results are reviewed by a senior advisory committee of pathologists, focusing on achieving diagnostic consensus and accurately correlating multiple expression patterns with current global classifications (e.g., WHO 2022/2025) and treatment guidelines (e.g., NCCN, ESMO). The package is geared towards resolving intractable diagnostic challenges and identifying multiple, overlapping therapeutic biomarkers.